<DOC>
	<DOCNO>NCT00034359</DOCNO>
	<brief_summary>The purpose study determine safety anti-HBV activity ACH-126 , 443 ( beta-L-Fd4C ) comparison lamivudine placebo treatment naive adult chronic Hepatitis B infection .</brief_summary>
	<brief_title>Safety Antiviral Activity Study ACH-126,443 ( Beta-L-Fd4C ) Treatment Naive Adults With Chronic Hepatitis B Virus Infection</brief_title>
	<detailed_description>Evaluation safety antiviral activity 3 dose level ACH-126 , 443 vs. lamivudine placebo 12 week treatment population describe .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Adults &gt; = 18 year age Chronic HBV infection , know HbsAg positive &gt; = 6 month Plasma HBV DNA level &gt; = 100,000 copies/mL HBeantigen positive HIV negative Basic hematologic chemistry parameter within acceptable limit ( define protocol No need exclude medication Subjects reproductive capability must utilize two approved form birth control , one must barrier protection . HIV infection Hepatitis C coinfection Concurrent systemic antiviral treatment Previous antiviral treatment HBV infection within 6 month prior randomization treatment 3TC 6 month time past Previous therapy agent significant systemic myelosuppressive cytotoxic potential within 3 month study start expect need therapy study start Alcohol abuse Pregnancy breastfeed Inability tolerate oral medication AST &gt; 7.0 time upper limit normal ALT &gt; 7.0 time upper limit normal Any clinical condition prior therapy , Investigators opinion , would make subject unsuitable study unable comply dose requirement Use investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>E-antigen positive</keyword>
	<keyword>Treatment Naive Chronic Hepatitis B , Achillion</keyword>
</DOC>